TRIBE; Tyrosine kinase inhibitor therapy in renal-cell carcinoma: Immune biomarker evaluation

被引：0
|
作者：
Villa, S. [1 ]
Pillai, M. [2 ]
Graham, D. [1 ]
Kilgour, E. [3 ]
Overton, N. [3 ]
Vasudev, N. [4 ,5 ]
Hughes, A. [6 ]
Walker, A. [1 ]
Dransfield, S. [1 ]
Thistlethwaite, F. [1 ]
机构：
[1] Christie NHS Fdn Trust, Expt Canc Med Team, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Canc Res UK Manchester Inst, Clin & Expt Pharmacol Grp, Manchester, Lancs, England
[4] Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England
[5] St Jamess Inst Oncol, Leeds, W Yorkshire, England
[6] Univ Manchester, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
10.1093/annonc/mdy315.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
58TiP
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [21] CURRENT THERAPY FOR RENAL-CELL CARCINOMA
    MCDONALD, MW
    JOURNAL OF UROLOGY, 1982, 127 (02): : 211 - 217
  • [22] Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy
    Tomas Buchler
    Alexandr Poprach
    Targeted Oncology, 2024, 19 : 175 - 180
  • [23] Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy
    Buchler, Tomas
    Poprach, Alexandr
    TARGETED ONCOLOGY, 2024, 19 (02) : 175 - 180
  • [24] Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy
    Neill, Mischel G.
    Wei, Alice C.
    Jewett, Michael A. S.
    UROLOGY, 2007, 70 (01) : 178.e9 - 178.e11
  • [25] Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
    Brookman-May, Sabine
    May, Matthias
    Gilfrich, Christian
    Wieland, Wolf Ferdinand
    Burger, Maximilian
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (06) : 813 - 823
  • [26] Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis
    Yoshida, Kazuhiko
    Nagasaka, Naoki
    Kondo, Tsunenori
    Kobari, Yuki
    Ishihara, Hiroki
    Fukuda, Hironori
    Iizuka, Junpei
    Ishida, Hideki
    Takagi, Toshio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (10) : 1538 - 1547
  • [27] Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
    Hiroki Ishihara
    Yuki Nemoto
    Kazutaka Nakamura
    Hidekazu Tachibana
    Hironori Fukuda
    Kazuhiko Yoshida
    Hirohito Kobayashi
    Junpei Iizuka
    Hiroaki Shimmura
    Yasunobu Hashimoto
    Tsunenori Kondo
    Toshio Takagi
    Targeted Oncology, 2023, 18 : 159 - 168
  • [28] Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Kondo, Tsunenori
    Takagi, Toshio
    TARGETED ONCOLOGY, 2023, 18 (01) : 159 - 168
  • [29] Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma
    Sekino, Yohei
    Teishima, Jun
    Liang, Gangning
    Hinata, Nobuyuki
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (12) : 1419 - 1428
  • [30] Pazopanib: An Oral Multitargeted Tyrosine Kinase Inhibitor for Use in Renal Cell Carcinoma
    LaPlant, Kourtney D.
    Louzon, Paige D.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (06) : 1054 - 1060
12345